In the past week, PGEN stock has gone down by -5.86%, with a monthly gain of 64.49% and a quarterly surge of 27.80%. The volatility ratio for the week is 9.03%, and the volatility levels for the last 30 days are 13.12% for Precigen Inc The simple moving average for the last 20 days is 13.57% for PGEN stock, with a simple moving average of -6.25% for the last 200 days.
Is It Worth Investing in Precigen Inc (NASDAQ: PGEN) Right Now?
The stock has a 36-month beta value of 1.64. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PGEN is 163.53M, and at present, short sellers hold a 10.67% of that float. On January 16, 2025, the average trading volume of PGEN was 1.32M shares.
PGEN) stock’s latest price update
Precigen Inc (NASDAQ: PGEN)’s stock price has plunge by -1.70relation to previous closing price of 1.13. Nevertheless, the company has seen a -5.86% plunge in its stock price over the last five trading sessions. prnewswire.com reported 2025-01-13 that – PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease – – Company completed BLA submission for PRGN-2012 for treatment of adults with RRP – – Commercial readiness activities underway in anticipation of potential launch of PRGN-2012; Company started 2025 with approximately $100 million cash on-hand* with cash runway well into 2026, beyond the anticipated launch in the second half of 2025 – – According to recently updated internal analysis derived from review of claims data, the market opportunity for PRGN-2012 in RRP is estimated to be approximately 27,000 adult patients in the US – – Immense market potential for AdenoVerse platform in other HPV6/11-driven indications, such as genital warts, which has significant unmet need with annual global incidence of more than 4 million and prevalence of more than 25 million, and HPV16/18-driven indications, such as cervical cancer and head and neck cancers – – Company presentation on Thursday, January 16, 2025 at 9:00 AM PT in San Francisco – GERMANTOWN, Md., Jan. 13, 2025 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced highlights for the upcoming company presentation at the 43rd Annual J.P.
Analysts’ Opinion of PGEN
Cantor Fitzgerald gave a rating of “Overweight” to PGEN, setting the target price at $7 in the report published on November 18th of the previous year.
PGEN Trading at 23.50% from the 50-Day Moving Average
After a stumble in the market that brought PGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.45% of loss for the given period.
Volatility was left at 13.12%, however, over the last 30 days, the volatility rate increased by 9.03%, as shares surge +67.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +37.73% upper at present.
During the last 5 trading sessions, PGEN fell by -4.66%, which changed the moving average for the period of 200-days by -21.33% in comparison to the 20-day moving average, which settled at $0.9786. In addition, Precigen Inc saw -0.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PGEN starting from Perez Jeffrey Thomas, who purchase 58,823 shares at the price of $0.85 back on Aug 09 ’24. After this action, Perez Jeffrey Thomas now owns 743,097 shares of Precigen Inc, valued at $50,000 using the latest closing price.
KIRK RANDAL J, the Director of Precigen Inc, purchase 23,529,411 shares at $0.85 during a trade that took place back on Aug 09 ’24, which means that KIRK RANDAL J is holding 64,547,214 shares at $19,999,999 based on the most recent closing price.
Stock Fundamentals for PGEN
Current profitability levels for the company are sitting at:
- -32.78 for the present operating margin
- -0.63 for the gross margin
The net margin for Precigen Inc stands at -35.22. The total capital return value is set at -2.09. Equity return is now at value -137.46, with -101.81 for asset returns.
Based on Precigen Inc (PGEN), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -13.17. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -9992.69.
Currently, EBITDA for the company is -89.23 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 77.98. The receivables turnover for the company is 5.44for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.63.
Conclusion
To sum up, Precigen Inc (PGEN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
